Use of Oral Cholera Vaccine in Haiti: A Rural Demonstration Project

被引：60

作者：

Ivers, Louise C. ^{[1
]}

Teng, Jessica E. ^{[1
]}

Lascher, Jonathan ^{[2
]}

Raymond, Max ^{[3
]}

Weigel, Jonathan ^{[4
]}

Victor, Nadia ^{[3
]}

Jerome, J. Gregory ^{[5
]}

Hilaire, Isabelle J. ^{[5
]}

Almazor, Charles P. ^{[6
]}

Ternier, Ralph ^{[7
]}

Cadet, Jean ^{[8
]}

Francois, Jeannot ^{[8
]}

Guillaume, Florence D. ^{[9
]}

Farmer, Paul E. ^{[4
]}

机构：

[1] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA

[2] Partners Hlth, Haiti Programs Dept, Boston, MA USA

[3] Zanmi Lasante, Programs Dept, St Marc, Haiti

[4] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA

[5] Zanmi Lasante, Monitoring & Evaluat, St Marc, Haiti

[6] Zanmi Lasante, Clin Serv, St Marc, Haiti

[7] Zanmi Lasante, Community Hlth Programs, St Marc, Haiti

[8] Minist Hlth & Populat, Expanded Immunizat Program, Port Au Prince, Haiti

[9] Minist Hlth & Populat, Port Au Prince, Haiti

来源：

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 2013年 / 89卷 / 04期

关键词：

OUTBREAKS; EPIDEMIC; SAFETY;

D O I：

10.4269/ajtmh.13-0183

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

A cholera epidemic has claimed the lives of more than 8,000 Haitians and sickened 650,000 since the outbreak began in October 2010. Early intervention in the epidemic focused on case-finding, treatment, and water and sanitation interventions for prevention of transmission. Use of oral cholera vaccine (OCV) as part of a complementary set of control activities was considered but initially rejected by policymakers. In December 2011, the Minister of Health of Haiti called for a demonstration of the acceptability and feasibility of the use of OCV in urban and rural Haiti. This paper describes the collaborative activity that offered OCV to one region of the Artibonite Department of rural Haiti in addition to other ongoing treatment and control measures. Despite logistics and cold chain challenges, 45,417 persons were successfully vaccinated with OCV in the region, and 90.8% of these persons completed their second dose.

引用

页码：617 / 624

页数：8

共 50 条

[31] Flexibility of Oral Cholera Vaccine Dosing-A Randomized Controlled Trial Measuring Immune Responses Following Alternative Vaccination Schedules in a Cholera Hyper-Endemic Zone
Kanungo, Suman
Desai, Sachin N.
Nandy, Ranjan Kumar
Bhattacharya, Mihir Kumar
Kim, Deok Ryun
Sinha, Anuradha
Mahapatra, Tanmay
Yang, Jae Seung
Lopez, Anna Lena
Manna, Byomkesh
Bannerjee, Barnali
Ali, Mohammad
Dhingra, Mandeep Singh
Chandra, Ananga Mohan
Clemens, John D.
Sur, Dipika
Wierzba, Thomas F.
PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (03):
[32] Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh
Chowdhury, Fahima
Bhuiyan, Taufiqur Rahman
Akter, Afroza
Bhuiyan, Md Saruar
Khan, Ashraful Islam
Hossain, Motaher
Tauheed, Imam
Ahmed, Tasnuva
Islam, Shaumik
Rafique, Tanzeem Ahmed
Siddique, Shah Alam
Harun, Nabila Binta
Islam, Khaleda
Clemens, John D.
Qadri, Firdausi
PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (03):
[33] The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study
Azman, Andrew S.
Luquero, Francisco J.
Ciglenecki, Iza
Grais, Rebecca F.
Sack, David A.
Lessler, Justin
PLOS MEDICINE, 2015, 12 (08)
[34] Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding
Ahmed, Tanvir
Svennerholm, Ann-Mari
Al Tarique, Abdullah
Sultana, Gazi N. N.
Qadri, Firdausi
VACCINE, 2009, 27 (09) : 1433 - 1439
[35] Optimized oral cholera vaccine distribution strategies to minimize disease incidence: A mixed integer programming model and analysis of a Bangladesh scenario
Smalley, Hannah K.
Keskinocak, Pinar
Swann, Julie
Hinman, Alan
VACCINE, 2015, 33 (46) : 6218 - 6223
[36] Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial
Jonker, Emile F. F.
Uijlings, Marjolein A. C.
Visser, Leonardus G.
Soonawala, Darius
VACCINE, 2019, 37 (23) : 3133 - 3139
[37] Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences
Kalkowska, Dominika A.
Wassilak, Steven G. F.
Wiesen, Eric
Burns, Cara C.
Pallansch, Mark A.
Badizadegan, Kamran
Thompson, Kimberly M.
RISK ANALYSIS, 2024, 44 (02) : 366 - 378
[38] Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh
Emperador, Devy M.
Velasquez, Daniel E.
Estivariz, Concepcion F.
Lopman, Ben
Jiang, Baoming
Parashar, Umesh
Anand, Abhijeet
Zaman, Khalequ
CLINICAL INFECTIOUS DISEASES, 2016, 62 (02) : 150 - 156
[39] Associations between biomarkers of environmental enteric dysfunction and oral rotavirus vaccine immunogenicity in rural Zimbabwean infants
Church, James A.
Rukobo, Sandra
Govha, Margaret
Gough, Ethan K.
Chasekwa, Bernard
Lee, Benjamin
Carmolli, Marya P.
Panic, Gordana
Giallourou, Natasa
Ntozini, Robert
Mutasa, Kuda
McNeal, Monica M.
Majo, Florence D.
Tavengwa, Naume, V
Swann, Jonathan R.
Moulton, Lawrence H.
Kirkpatrick, Beth D.
Humphrey, Jean H.
Prendergast, Andrew J.
ECLINICALMEDICINE, 2021, 41
[40] Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial
McCarty, James M.
Lock, Michael D.
Bennett, Sean
Hunt, Kristin M.
Simon, Jakub K.
Gurwith, Marc
VACCINE, 2019, 37 (11) : 1389 - 1397

← 1 2 3 4 5 →